FREE LIVE WEBCASTS

Business Uninterrupted: SAP Upgrade in a Validated Environment
Thursday, February 25, 2010 at 11:00 AM PT; 2:00 PM ET

Join us to learn how Astrazeneca has overcome acute challenges of a validated environment to achieve a near-perfect upgrade by upgrading their SAP platform and partnering with Infosys Technologies Ltd., and all this while the world was seeing its worst economic downturn yet. Detlef Geigle, Head Technical Services & Architecture at Novartis Pharmaceuticals AG shares his insights on how good teams can bring about Great results in an SAP Upgrade. Niraj Bangad – Senior Project Manager at Infosys Technologies Ltd. walks you through the detailed SAP Upgrade journey that led to a best-in-class experience for Astrazeneca.

Register Free at http://pharmexec.com/sap

Sponsor:
Infosys Technologies Ltd.


The New Landscape for Compliance with Medical Speaker Programs
Thursday, March 11, 2010 at 11:00 AM PT; 2:00 PM ET

This webcast will address recent developments and current trends in the regulation of medical speaker programs. It will review state-by-state changes in regulations, pending changes at the state and federal level, and trends among healthcare providers and associations to limit speaker program participation. Two leading experts in the field will provide practical advice on how to reposition speaker programs to align with new regulations and perceptions in healthcare. The potential impact of the Physicians Payment Sunshine Act and other measures towards greater transparency will be discussed. Alternatives to traditional venue-based programs, including the use of virtual media programs such as live web conferencing, will be evaluated. The webcast will conclude by reviewing best practices in the conduct of effective and compliant speaker programs.

Register Free at http://www.medpt.com/pharmexec/compliance/

Sponsor:
Medpoint Communications Inc.


Maximizing Return on Information: A Google Case Study
Wednesday, March 17, 2010 at 11:00 AM PT; 2:00 PM ET

Effective management of the R&D innovation cycle is critical to the long-term profitability of pharmaceutical and life sciences companies.  Yet for most organizations, the process takes too long; according to the Pharmaceutical and Research Manufacturers of America (PhRMA), the average time from discovery and development to final market authorization for a new drug can take 12 to 15 years, leaving only 5 to 8 years of effective patent protection.  Increasing the pace of innovation to commercialization has thus become a high priority for the entire life sciences industry. More

Register Free at http://pharmexec.com/enterprise

Sponsor:
Google

ON-DEMAND WEBCASTS NOW AVAILABLE FOR REPLAY

Applying E-Commerce to Support Discovery and Development of Medicines: Key Lessons and Learnings
Recorded on: December 15, 2009

Join us to learn how LIFE Technologies has applied a new approach to E-Commerce to drive improvements in customer experience and satisfaction, achieving higher levels of revenue growth. Christian Wip, IT Director for eBusiness at Life Technologies shares his insights on how E-Commerce was leveraged as a primary channel to improve efficiencies in the sales model, creating an added-value driver of revenue growth. And Guneet Paintal the Principal Consultant at Infosys Technologies Ltd., walks you through the detailed E-Commerce transformation journey that created a best-in-class online experience at LIFE Technologies.

Register Free at http://www.pharmexec.com/mining

Sponsor:
Infosys and Sterling Commerce

How Virtual Media Can Save the Medical Speaker Program
Recorded on: December 8, 2009

This webcast will address how the medical speaker program must evolve in response to major changes in medicine and the bio-pharma industry. It will review issues of economics, regulations, physician practice patterns, and public perception, which in combination have contributed to decline in speaker program activity. Two leading experts in the field will discuss the win-win value of industry support for peer speaker activities and provide practical advice on how to reposition these programs to align with new business models. Virtual media alternatives to traditional venue-based programs will be discussed, ranging from satellite broadcasts to live webconferences. Best practices in the design and execution of virtual speaker programs will be highlighted, so that medical product marketers can realize the full potential of this emerging format for peer-based learning.

Register Free at http://pharmexec.com/speaker

Sponsor:
MedPoint Communications, inc.

Risk, Reward and the Pharmaceutical Life Cycle: Managing Information as a Strategic Productivity Asset
Recorded on: December 2, 2009

Major changes are underway in the reporting and enforcement environment for drug safety, with new regulations now in place in the US and Europe that require sponsoring companies to provide timely, comprehensive and accurate information to authorities, virtually on demand. REMS, RMPs, RiskMAPS, the Sentinel Initiative and other FDA programs geared to identifying product safety risks before they emerge as public health challenges raise the bar on what the sponsors must do to comply. These include making significant investments in upgrading the quality and scope of data to track the impact of a medicine's use on the patient community at every stage of its life cycle, from clinical trials to post marketing surveillance in the latter case, this can now include obligations to monitor safety and risk well beyond the time of patent expiry. In this new regulatory environment, information must be accessible and relevant for quick release to meet strict regulatory goal posts. It also has to be needs appropriate, with controls in place to ensure the confidentiality of what for knowledge-based industries like pharmaceuticals is a key strategic asset. Customized technologies and resource platforms can make this process more efficient by standardizing document distribution, on a global basis, and allowing the detailed analysis demanded in sensitive areas like adverse event reporting.

Register Free at www.pharmexec.com/risk

Sponsor:
IntraLinks

Building Market Share Through Patient Segmentation Strategies: New Ideas and Best Practices to Enhance ROI
Recorded on: December 3, 2009

Pharmaceutical and medical device marketers confront growing pressure to demonstrate return on investment [ROI] in consumer advertising and brand awareness. Real metrics of performance against budgeted ad dollars are critical, especially as available resources shrink .In this webcast, you’ll learn how consumer segmentation analysis can improve return on investment and lead to the application of interactive media strategies in a way that is more engaging and effective than reliance on television, magazines and other traditional mass media.

Register Free at www.pharmexec.com/marketshare

Sponsor:
Healthgrades

Disclosure of Drug Promotion Expenses: How Automated Reporting and Master Data Management Can Improve Compliance and Lower Costs
Recorded on: October 28, 2009

Compliance with new US state laws and regulations that require disclosure of promotion, marketing and advertising expenses represent a growing cost and administrative burden for life sciences companies. More important, incomplete or inaccurate customer data can lead to noncompliant reporting and puts companies at risk for large fines. Join us to discuss the current regulatory environment on promotion disclosure and the vital role that customer master data management plays in compliance reporting. Learn about cost effective solutions to ensure uniform compliance with state and aggregate reporting requirement rules, including data collection and analysis, security protections, report distribution and management, and technology applications. The focus will be on addressing the challenge through practical steps ? how to avoid common pitfalls in compliance and stay current with legislative changes that are likely to accelerate as external pressures on industry promotional practices increase.

Register Free at www.pharmexec.com/disclosure

Sponsor:
Cegedim Dendrite

Drugs, Devices or Data – Which is Most Valuable? An Expert Panel Debates
Recorded on: September 24, 2009

Regulatory compliance and sales operations effectiveness have never been more important for the Pharmaceutical and Medical Devices companies. But what's the best way to confront these increasingly complex problems? Join us for a lively discussion on technology and trends in the Health and Life Sciences industry, and hear firsthand how leading companies like Boehringer Ingelheim are confronting and solving their compliance and sales operations challenges using Master Data Management. A distinguished panel of experts from AMR Research, Boehringer Ingelheim, IBM GBS, and Siperian will be on hand to lead the discussion.

Register Free at www.pharmexec.com/valuable

Sponsor:
Siperian

Develop Competitive Advantage Through Business Analytics in the New Pharmaceutical Commercial Model
Recorded on: September 14, 2009

As we all know, the industry is facing trends that will continue to erode profitability if the sales and marketing model does not change. The image of a new commercial model is now starting to emerge - and although the details are far from clear, the basic components are there in terms of some of the things that the industry needs to achieve. One of the trends in the new commercial model is for companies to make smarter sales and marketing decisions based on deeper analytical insights - and to develop these competencies in house to create a clear and distinct competitive advantage. Organizations that use business analytics today drive value and better decisions across the business - and those that make the better decisions now are the ones who will ultimately succeed in the new commercial model. The Webcast will help corporate decision makers like you better understand why transformational business analytics is a game changer for Pharma that will:

• Uncover real intelligence within your organization.
• Solve complex business problems.
• Help you understand who your high-value customers are.
• Create a clear and distinct competitive advantage.
  
• Drive sustainable growth through innovation.

Register Free at www.pharmexec.com/businessanalytics

Sponsor:
SAS

An Evolving Standard for Success: Proving Product Value Through Comparative Effectiveness Data
Recorded on: September 10, 2009

Inclusion of $1.1B in the Obama Stimulus Plan to support comparative effectiveness research of drugs, medical devices, surgical procedures and other treatments, is a clear indication of the US Government's priority to obtain value in healthcare dollar spending. As it gains traction among policymakers, and as the Federal Government continues to increase its role as the largest direct payer for drugs, biologics, devices and diagnostics, we expect regulators to demand such data for new products demonstrating greater benefits over existing products. In this webcast learn: the definition of comparative effectiveness, and an overview of the current US regulatory status, and outlook for future state. In addition to how comparative effectiveness data is generated and utilized in product development and post-marketing, and how to develop a prioritized plan of action to assess and analyze your product portfolio: early stage through marketed products.

Register Free at www.appliedclinicaltrialsonline.com/comparativeeffectiveness

Sponsor:
PAREXEL

Clinical Study Data Integration - the Art and the Promise
Recorded on: July 8, 2009

In the life sciences industry, the process of clinical development requires that patient data collected from multiple sources be merged and combined for the purpose of understanding the safety and efficacy of a compound. Quick and accurate access to this combined data can:

• Inform management decisions to alter, accelerate, or cancel the development of a particular compound and thus increase profits
• Deliver data for formal structured analysis to accelerate regulatory submissions
• Minimize the risk of introducing an unsafe compound to the market

Register Free at www.appliedclinicaltrialsonline.com/integration

Sponsor:
Oracle Health Sciences

The Unvarnished Truth about Comparative Effectiveness
Recorded on: June 25, 2009

The mere mention of the term "comparative effectiveness" evokes a host of reactions among pharmaceutical manufacturers: confusion, skepticism, even fear. President Obama has called for a national agency for comparative effectiveness. Congress introduced a bill in summer 2008 that would have set the stage for comparative effectiveness at a federal level. No one doubts that comparative effectiveness is coming to healthcare - but what will it encompass? How will comparative effectiveness impact access to medications? What can manufacturers do to prepare? More

Register Free at www.pharmexec.com/effectiveness

Sponsor:
AmerisourceBergen Specialty Group

Data driven laboratory asset management programs - Unlock unknown capital and drive efficiency while improving quality and scientist experience
Recorded on: June 17, 2009

With increasing pressure in the pharmaceutical and biotech industry to reduce the costs of developing new drugs, more companies are looking at consolidating suppliers and partnering with global providers to enable them gain economies of scale, unify processes and increase productivity across all sites and functions. More companies are starting to focus on their laboratory assets, how these are maintained, how validation is carried out, how downtime affects their operations and scientists' productivity, how those assets are being utilized and whether they have over/under capacity. Our lifecycle asset management programs go well beyond asset maintenance and provide you with a future proof solution that will improve scientist productivity, support capital investment strategies, help drive efficiency through multiple functions without compromising quality or scientist experience.

Register Free at www.pharmexec.com/datadriven

Sponsor:
GE Healthcare

Video: Early Phase Strategies to Increase the Success of Later Phase Trials
Recorded on: May 27, 2009

Many pharmaceutical and biotech organizations miss the opportunity to develop Early Phase strategies to transition to Later Phase success. For example, 41% of all New Drug Applications (NDAs) fail due to insufficient information on the optimal dose. By including "real patient" populations in Phase I/IIa studies, these organizations could: Obtain data from the type of patients who will eventually be used in Phase III trials. Devise population modeling and simulation techniques to eliminate the effects of co-variates and improve Proof-of-Concept.

Register Free at www.pharmexec.com/earlyphase

Sponsor:
Quintiles

Wanted: A Single Version of the Truth for Your Customer Data
Recorded on: May 20, 2009

The Life Sciences industry faces many challenges as they close out the first decade of the new millennium. Well documented as one of the most highly regulated Industries, companies are faced with maintaining compliance while operating in an era of corporate downsizing. The solution is rooted in the often underestimated area of master data management. Join us for this free live webcast, featuring a panel of industry experts who will share practical insights to help you improve your business processes starting from their very foundation.

Register Free at www.pharmexec.com/truth

Sponsor:
Cegedim Dendrite

Video: Transforming Sales & Marketing Given Today's Pharma Realities: A New Model for Success
Recorded on: May 12, 2009

The world’s top pharmaceutical markets have hit maturity. Growth has slowed, especially in primary care, and companies are shifting to a specialty focus. Have your sales and marketing strategies adapted to this new reality? Over the past decade, and especially over the last three years, the largest pharma markets have been utterly transformed. Tried and true strategies can no longer keep up. Across the industry, executives are asking:
Exactly how much are companies overspending on promotion or misdirecting budgets to unproductive activities?
What are the implications of this as they look for way to further cut costs and reduce infrastructure?
Which commercial model will make the most efficient use of resources given rising consumer and payer demand, increased competition/genericization and a growing specialty product focus?

Register Free at www.pharmexec.com/commercialmodels

Sponsor:
IMS Health

Understanding the Complexities of State Licensing and VAWD
Recorded on: April 21, 2009

The changing environment surrounding the requirements for state licensure of manufacturers and wholesalers can be difficult to understand. Knowing the importance and your responsibility surrounding VAWD and the definitions around "wholesaler" and "manufacturer" are unclear to many companies. Join us to discuss industry challenges, and hear from experts who have successfully managed the complexities and dynamics of state licensure. Hear what is being done as an industry to understand and monitor the complex database of rules and regulations that define "wholesale distribution". And learn about cost effective solutions to ensure compliance with state licensing requirements and how to best stay current with future legislative changes in this complex environment.

Register Free at www.pharmexec.com/VAWD

Sponsor:
Cegedim Dendrite

Revolutionizing KOL Relationship Management for Maximum Impact
Recorded on: February 24, 2009

2009 promises to bring increased regulatory and financial scrutiny to the life sciences industry as new regulations and public health policy reforms loom on the horizon. This will force pharmaceutical companies to change the ways they interact with key physicians and opinion leaders in an effort to increase transparency and ethical outcomes.  To address these issues, a forward-thinking Key Opinion Leader (KOL) Management strategy is required to ensure regulatory compliance that enables knowledge sharing, communication, and visibility. As a result, your team will develop trusted, credible scientific peer relationships between your company, your MSLs and thought leaders. click here.

Register Free at www.pharmexec.com/KOL

Sponsor:
Cegedim Dendrite

No More Tiers! A New Approach for Evaluating Formulary Contracts
Recorded on: February 11, 2009

Since the adoption of three tier benefit designs by insurers and PBMs in the early 1990’s, Pharmaceutical Executives have argued about the value of contracting for preferred (Tier 2) status for their brands. Managed care executives within Pharma have been measured primarily in terms of the percent of lives having Tier 2 access. Brands and sales forces have blamed a lack of Tier 2 access for not achieving their uptake goals. But what is that Quality of Access for Tier 2, how has it changed over time and how much does it actually differ from Tier 3? Where does it differ significantly? Does it matter? Does it matter enough to pay the rebates expected by Managed Care plans? click here.

Register Free at www.pharmexec.com/tiers

Sponsor:
Amundsen Group and Wolters Kluwer Health